[1] Wiest R,Garcia-Tsao,G. Bacterial translocation (BT) in cirrhosis.Hepatology,2005,41:422-433.
[2] Nolan JP.The role of intestinal endotoxin in liver injury:a long and evolving history.Hepatology,2010,52:1829-1835.
[3] Arab JP,Karpen SJ,Dawson PA,et al. Bile acids and nonalcoholic fatty liver disease molecular insights and therapeutic perspectives.Hepatology,2017,65:350-362.
[4] Jiang C,Xie C,Li F,et al.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.J Clin Invest,2015,125:386-402.
[5] Ridlon JM,Kang DJ,Hylemon PB,et al.Bile acids and the gut microbiome.Curr Opin Gastroenterol,2014,30:332-338.
[6] Kim YS,Ho SB.Intestinal goblet cells and mucins in health and disease:recent insightsand progress.Curr Gastroenterol Rep,2010;12:319-330.
[7] Andrianifahanana M,Moniaux N,Batra SK,et al.Regulation of mucin expression: mecha-nistic aspects and implications for cancer and inflammatory diseases.BiochimBiophys Acta,2006,1765:189-222.
[8] Xie YR,Liu SL,Liu X,et al.Intestinal microbiota and innate immunity-related gene altera-tion in cirrhotic rats with liver transplantation.Transplant Proc,2011,43:3973-3979.
[9] Grewal RK,Mahmood A.Ethanol induced changes in glycosylation of mucins in rat intestine.Ann Gastroenterol,2009,22:178-183.
[10] Hartmann P,Chen P,Wang HJ,et al.Deficiency of intestinal mucin-2 ameliorates experim-ental alcoholic liver disease in mice.Hepatology,2013,58:108-119.
[11] Vaishnava S,Behrendt CL,Ismail AS,et al.Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface.Proc Natl Acad Sci USA.2008;105:20858-20863.
[12] Ayabe T,Satchell DP,Wilson CL,et al.Secretion of microbicidal alpha-defensins by intesti-nal Paneth cells in response to bacteria.Nat Immunol,2000,1:113-118
[13] Ogle CK,Noel JG,Guo X,et al.The ability of endotoxin-stimulated enterocytes to produ-ce bactericidal factors.Crit Care Med,2002,30:428-434.
[14] Qin J, Li R,Raes J,et al.A human gut microbial gene catalogue established by metagenomic sequencing.Nature,2010,464:59-65.
[15] Chen Y,Yang F,Lu H,et al.Characterization of fecal microbial communities in patients with liver cirrhosis.Hepatology,2011,54:562-572.
[16] Bajaj JS,Heuman DM,Hylemon PB,et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications.J Hepatol,2014,60:940-947.
[17] Iwakiri Y,Shah V,Rockey DC.Vascular pathobiology in chronic liver disease and cirrhosis-current status and future directions.J Hepatol,2014,61:912-924.
[18] Marrone G,Shah VH,Gracia-Sancho J.Sinusoidal communication in fibrosis and regener-ation. J Hepatol,2016,65:608-617.
[19] Wiest R,Groszmann RJ.The paradox of nitric oxide in cirrhosis and portal hypertension: too much,not enough.Hepatology,2002,35:478-491.
[20] Arab JP,Karpen SJ,Dawson PA,et al.Bile acids and nonalcoholic fatty liver disease:molecular insights and therapeutic perspectives.Hepatology,2017,65:350-362.
[21] Verbeke L,Farre R,Verbinnen B,et al.The FXR agonis obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 2015,185:409-419.
[22] Verbeke L,Farre R, Trebicka J,et al.Obeticholic acid,a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology,2014,59:2286-2298.
[23] Chen Y,Yang F,Lu H,et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology,2011,54:562-572.
[24] Cardenas A,Mendez-Bocanegra A. Report of the Baveno VI Consensus Workshop.Ann Hepatol,2016,15:289-290.
[25] Rogers GB,van der Gast CJ,Bruce KD,et al. Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension. PLoS One,2013,8:e74884.
[26] Bajaj JS,Ridlon JM,Hylemon PB,et al.Linkage of gut microbiome with cognition in hep-atic encephalopathy.Am J Physiol Gastrointest Liver Physiol,2012,302:G168-G175.
[27] Moratalla A,Ampuero J,Bellot P,et al.Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy.Liver Int,2017,37:212-223.
[28] Ponziani FR,Zocco MA,Senzolo M,et al.Portal vein thrombosis and liver transplantation:implications for waiting list period,surgical approach,early and late follow-up.Transplant Rev (Orlando),2014,28:92-101.
[29] Wosiewicz P,Zorniak M,Hartleb M,et al.Portal vein thrombosis in cirrhosis is not associated with intestinal barrier disruption or increased platelet aggregability.Clin Res Hepatol Gastroenterol,2016,40:722-729.
[30] Bajaj JS,Heuman DM,Hylemon PB,et al.Randomised clinicaltrial:Lactobacillus GG modulates gut microbiome,metabolome and endotoxemia in patients with cirrhosis.Aliment Pharmacol Ther,2014,39:1113-1125.
[31] Bajaj JS,Heuman DM,Hylemon PB,et al.Randomised clinical trial:Lactobacillus GG modulates gut microbiome,metabolome and endotoxemia in patients with cirrhosis.Aliment Pharmacol Ther,2014,39:1113-1125.
[32] Dhiman RK,Rana B,Agrawal S,et al.Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis:a randomized,controlled trial.Gastroenterology,2014,147:1327-1337 e1323.
[33] Lin TC,Hung YP,Ko WCl,et al.Fecal microbiota transplantation for Clostridiumdifficile infection in Taiwan:establishment and implementation.J Microbiol Immunol Infect,2019,52:841-850.
[34] Qin N,Yang FL,Li A,et al.Alterations of the Human Gut Microbiome in Liver Cirrhosis.Nature,2014,513:59-64. |
